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A systematic review of non-antibiotic
measures for the prevention of urinary
tract infections in pregnancy
Flavia Ghouri, Amelia Hollywood* and Kath Ryan
Abstract
Background: Urinary tract infections (UTIs) are common in pregnancy and account for the highest proportion of
primary care antibiotic prescriptions issued to pregnant women in the UK. It is well known that antibiotic use is
associated with increased antimicrobial resistance and therefore measures to minimise antibiotic use for UTI
prevention have been studied. The efficacy and safety of these measures in pregnancy have not been addressed
and therefore the aim of this study was to systematically review the literature to identify and evaluate potential
measures to prevent UTIs in pregnant women.
Methods: Ten databases (EMBASE, AMED, BNI, CINAHL, Medline, PubMed, PsycINFO, Cochrane Trials, Scopus and
Science Direct) were systematically searched in July 2017 for studies reporting non-antibiotic measures to prevent
UTIs in pregnancy. The terms (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention) AND (pregnan*)
were used. The quality of the publications was appraised using the Critical Appraisal Skills Programme (CASP) checklists
for cohort study, case-control study and randomised controlled trial. The results were synthesised using a textual
narrative approach.
Results: Search results yielded 3276 publications and after reviewing titles and removing duplicates, 57 full text articles
were assessed for eligibility and eight were included in the review. Five different approaches (hygiene measures,
cranberry juice, immunisation, ascorbic acid and Canephron® N) have been identified, all of which are reported to be
safe in pregnancy.
Conclusion: The quality of the evidence varied considerably and only hygiene measures were supported by evidence
to be recommended in practice. Future work needs to concentrate on strengthening the evidence base through
improved design and reporting of studies with a focus on immunisation, ascorbic acid and Canephron® N.
Keywords: Systematic review, Non-antibiotic measures, Prevention, Urinary tract infection, Antimicrobial resistance,
Pregnancy, Behaviour change
Background
Urinary tract infections (UTIs) account for the highest
proportion of primary care antibiotic prescriptions issued
to pregnant women in the UK [1]. Pregnant women have
an increased susceptibility to UTIs because of physio-
logical changes. The growing uterus can result in urinary
retention which predisposes the woman to infection. In
addition, hormonal fluctuations relax the ureteral muscle
and cause accumulation of urine in the bladder which also
increases the chance of developing a UTI [2].
Treatment of UTIs is recommended in pregnancy if
bacteria are detected in the urine even if there are no
accompanying symptoms i.e. in asymptomatic bacteri-
uria (ASB) [3]. Both ASB and symptomatic UTIs in
pregnancy are risk factors for the development of pyelo-
nephritis which can result in severe maternal morbidity
[4]. It is estimated that 20–30% of women with bacteri-
uria in the first trimester go on to develop pyelonephritis
in later trimesters [5]. Therefore, although ASB on its
own is not treated in the general population, guidelines
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published by the European Urological Association
(EAU) [3] and Scottish Intercollegiate Guidelines Net-
work (SIGN) [6] recommend screening and treating bac-
teriuria with or without symptoms. The current
management strategy according to these guidelines is to
use a short course of antibiotics.
Whilst antibiotics are vital in eradication of UTIs,
antimicrobial resistance due to their use is a global
health threat [7, 8]. Antimicrobial resistance means that
bacteria can survive antibiotic treatment and cause ser-
ious or life threatening infections. Use of antibiotics is
strongly associated with increasing emergence of resist-
ant bacteria and subsequent redundancy of antibiotics i.
e. previously effective antibiotics are losing their effi-
cacy [8, 9]. Unlike the general population, the choice of
safe antibiotics in pregnancy is limited because of
teratogenic potential e.g. quinolones should be avoided
in pregnancy because of a risk of joint malformations
in the foetus. Therefore antibiotics becoming ineffective
due to antimicrobial resistance is a particular concern
in pregnancy as it further limits the range of drugs
available to treat infections safely [10]. An example of
this in practice is the replacement of trimethoprim with
nitrofurantoin as the first line antibiotic to treat UTIs
[11] because of an increase in resistance due to its
widespread use in the UK [12]. Use of antibiotics can
also result in carriage of resistant bacteria by individ-
uals for a period of several months to a year after com-
pleting a course of antibiotics [13]. The resistant
bacteria can transfer to close physical contacts and may
colonise and infect subsequent hosts. This is especially
of concern in pregnancy as women can pass on resist-
ant bacteria to the neonate during birth, which is when
they are most vulnerable to infection. An example of
resistance specific to obstetric practice is the increase
in ampicillin resistant neonatal infections due to mater-
nal use of ampicillin [14, 15].
As well as contributing to antimicrobial resistance, anti-
biotic use in pregnancy also carries the risk of being harm-
ful to the foetus. Recently, a study has found a link
between antibiotic use and increased risk of spontaneous
miscarriages [16]. Another study assessing the effects of
nitrofurantoin, trimethoprim-sulfamethoxazole and ceph-
alosporins which are used to treat UTIS, found an
increased risk of birth defects such as oral clefts,
oesophageal and anorectal abnormalities in the offspring
[17]. In addition, research has also found an association
with antibiotic use in pregnancy and functional impair-
ment in children later on in life [18].
In light of the risks, it is essential that the use of anti-
biotics in pregnancy is carefully considered with a bal-
ance struck between the risks and benefits of these
drugs. The UK’s 5 year antimicrobial resistance strategy
[19] developed by the Department of Health (DH) and
Department for Environment Food and Rural Affairs
(Defra) identifies seven key areas where action is needed
to tackle antimicrobial resistance. One of these key areas
is ‘improving infection prevention and control practices’
which will lead to a reduction in the use of antibiotics as
infection rates will be minimised. Improving infection
prevention is also one of the main recommendations of
‘The Review on Antimicrobial Resistance’ (2016), chaired
by economist Jim O’Neill [8]. Non-antibiotic measures
to minimise antibiotic use for UTI prevention have been
studied but the efficacy and safety of these measures in
pregnancy have not been addressed [20]. Therefore, the
aim of this systematic review is to identify alternate
measures reported in scientific literature which may be
used to prevent UTIs in pregnancy. The benefits of non-
antibiotic measures to prevent UTIs in pregnancy are
two-fold. Firstly, the reduced use of antibiotics will mean
that they remain effective for longer, and secondly,
medication which is potentially harmful in pregnancy
can be avoided.
Methods
Ten databases (EMBASE, AMED, BNI, CINAHL, Med-
line, PubMed, PycINFO, Cochrane Trials, Scopus and
Science Direct) were searched and the final search string
was conducted in July 2017. The inclusion criteria accord-
ing to PICOS (see Table 1) consisted of studies reporting
non-antibiotic measures for the prevention of UTIs in
pregnant women.
Studies conducted exclusively in non-pregnant groups
or in conditions such as diabetes or spinal cord injury
were excluded. Search terms were; P: (pregnan*), I: (pre-
vention or control or management), O: (“urinary tract
infection” or UTI or bacteriuria or cystitis) as shown in
Table 2.
The search terms ‘control’ or ‘management’ were ini-
tially used but these terms did not yield relevant results
therefore this paper focuses on prevention only. The
final search strategy is available in Additional file 1.
A manual search of references from included studies
was also conducted. The quality of the publications was
appraised using the Critical Appraisal Skills Programme
(CASP) checklists for cohort study, case-control study
and randomised controlled trial [21–23]. The results
Table 1 Inclusion criteria (PICOS)
Population Pregnant Women
Intervention Non-antibiotic prevention measures
Comparator Any e.g. a placebo
Outcome Incidence of bacteriuria or UTI
Study Design Any e.g. randomised control trial (RCT) or observational
study
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were analysed and discussed using a narrative synthe-
sis approach.
Results
Search results yielded 3276 publications and after
reviewing titles and removing duplicates, 56 full text ar-
ticles and one conference abstract were assessed for
eligibility by FG and eight were included in the review
as shown in Fig. 1. The results identified five different
measures (hygiene behaviour, cranberry juice, immun-
isation, ascorbic acid and Canephron® N) which can be
used for the prevention of UTIs in pregnancy. Quality
appraisal of the included publications using the CASP
checklists is shown in Tables 3, Table 4 and Table 5.
Table 2 Search strategy
Database Search terms Results
EMBASE (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 744
AMED (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 0
BNI (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 10
CINAHL (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 66
Medline (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 397
PubMed (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 942
PsycINFO (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 4
Cochrane Trials (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 102
SCOPUS (TITLE-ABS-KEY (“urinary tract infection” OR UTI OR bacteriuria OR cystitis) AND TITLE-ABS-KEY (prevention or control or
management) AND TITLE-ABS-KEY (pregnan*) AND NOT TITLE-ABS-KEY (catheter OR catheter AND associated) AND NOT
TITLE-ABS-KEY (antibacterial* OR antibiotic* OR antimicrobial*)
Note: additional terms searched using ‘NOT’ due to too many results
1008
ScienceDirect (“urinary tract infection” or UTI or bacteriuria or cystitis) AND (prevention or control or management) AND pregnan* 3
Manual search 0
Total 3276
Fig. 1 Identification of publications
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The characteristics of the publications are included in
Table 6.
Hygiene behaviour
Three observational studies were identified which inves-
tigated the association between sexual and genital hy-
giene behaviours of pregnant women and the incidence
of asymptomatic bacteriuria (defined as > 105 colony
forming units/ml of urine) or symptomatic UTIs. One
study by Badran et al. [24] was not included in the
review due to repetition of results from a previously
conducted study.
The study by Amiri et al. [25] was a case-control study
which included 100 cases matched to 150 controls i.e.
total of 250 pregnant women. The two groups were
compared in terms of differences in genital hygiene or
sexual activity. The study by Elzayat et al. [26] was an
observational cohort study that included 170 pregnant
women between the ages of 18–41. Participants in this
study were administered a questionnaire about their
hygiene behaviours and a urine sample was tested to
determine the prevalence of bacteriuria. Both studies
show that hygiene behaviours are associated with the
incidence of UTIs.
Cranberry juice
There were two studies that assessed the effectiveness of
cranberry juice in preventing UTIs during pregnancy.
Wing et al. [27] conducted a randomised controlled trial
with 188 pregnant women under 16 weeks of pregnancy
and compared the efficacy of cranberry juice with a
placebo. There was a 57% reduction in bacteriuria and
41% reduction in all UTIs reported in this trial. Essadi et
al. [28] conducted a randomised controlled trial that
compared cranberry juice with water in 760 pregnant
women. They also reported positive results for the
effectiveness of cranberry juice and 70.5% of the partici-
pants who drank cranberry juice showed a significant
Table 3 Quality appraisal using CASP checklist for cohort studies
CASP cohort study checklist
Elzayat et al. 2017 [26] Baertschi et al. 2003 [29] Ordzhonikidze et al. 2009 [32]
Did the study address a clearly focused issue? Yes Yes Yes
Was the cohort recruited in an acceptable way? Yes Yes Can’t tell
Was the exposure accurately measured to minimise bias? Yes Yes Can’t tell
Was the outcome accurately measured to minimise bias? Yes Yes Can’t tell
(a) Have the authors identified all important confounding
factors?
Yes Yes Yes
(b) Have they taken account of the confounding factors
in the design and/or analysis?
Yes Yes Yes
(a) Was the follow up of subjects complete enough? Not applicable Yes Yes
(b) Was the follow up of subjects long enough? Not applicable Yes Yes
How precise are the results? Can’t tell (no CI given) Can’t tell (no CI given) Can’t tell (no CI given)
Do you believe the results? Yes Yes Yes
Can the results be applied to the local population? Yes Yes No (study population not clearly
defined)
Do the results of this study fit with other available evidence? Yes Yes Yes
Does the study have implications for practice? Yes Yes Yes
CI Confidence interval. Significance: p ≤ 0.05
Table 4 Quality appraisal using CASP checklist for case-control
studies
CASP case-control study checklist
Amiri et al. 2009 [25]
Did the study address a clearly focused
issue?
Yes
Did the authors use an appropriate
method to answer their question?
Yes
Were the cases recruited in an acceptable
way?
Yes
Were the controls selected in an acceptable
way?
Yes
Was the exposure accurately measured to
minimise bias?
Yes (but questionnaire
completed by midwives)
Have the authors taken account of the
potential confounding factors in the
design and/or in their analysis?
Yes
Were the results and risk estimate precise? Yes
Do you believe the results? Yes
Can the results be applied to the local
population?
Yes
Do the results of this study fit with other
available evidence?
Yes
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reduction in UTIs compared to 32.16% of women who
drank water.
Immunisation
Immunisation as a means of preventing UTIs in preg-
nancy was assessed by two studies. Baertschi et al. [29]
conducted a before-after study using a bacterial extract
in 62 women who were 16–28 weeks pregnant. Use of
the extract significantly reduced the incidence of UTIs
and recurrence rates fell from 52.5% prior to using the
extract to 19.4% after women started using the extract.
Grischke and Ruttgers [30] investigated the effectiveness
of an intramuscular vaccine in an open randomised trial.
A total of 400 women were included in the trial and a
significant difference was seen in the incidence of UTIs
in the trial (28 infections) and control groups (84 infec-
tions) suggesting a beneficial effect of the vaccine.
Ascorbic acid
Ochoa-Brust et al. [31] conducted a RCT to evaluate
whether daily intake of ascorbic acid (100 mg) prevented
UTIs in pregnancy. There was a total of 110 pregnant
women, 55 in the trial group and 55 in the control
group. The infection percentage was 12.7% in women
who were given daily ascorbic acid compared with 29.1%
in women who received the comparator.
Canephron® N
Ordzhonikidze et al. [32] conducted a cohort study in
300 pregnant women using Canephron® N which is a
herbal product. Women were divided into two groups,
those who had a current UTI and those who suffered
with chronic urinary tract problems but did not have a
current exacerbation. The results show that the fre-
quency of pyelonephritis was 1.5 times less in the first
group and 1.3 times less in the second group due to use
of this product.
Discussion
The five different measures (hygiene behaviour, cranberry
juice, immunisation, ascorbic acid and Canephron® N)
highlighted in the review vary in the evidence supporting
their use for the prevention of UTIs in pregnancy.
Hygiene behaviour
The EAU guideline for urological infections states that
studies investigating hygiene behaviours have not found
any association with the incidence of UTIs [3]. The two
observational studies included in this review, however,
provide evidence that hygiene behaviours are associated
with the incidence of UTIs. Results show that increased
sexual activity of greater than two or three times a week
was linked to a high frequency of UTIs. However, wash-
ing the genital area and voiding the bladder after inter-
course had a protective effect. The direction of wiping
the genital area after voiding the bladder was also found
to be important and women who wiped from back to
front had a higher incidence of UTIs according to both
studies. Lastly, Amiri et al. [25] also found that drinking
Table 5 Quality appraisal using CASP checklist for randomised controlled trials
CASP randomised control study checklist
Ochoa-Brust et al. 2007 [31] Grischke et al. 1987 [30] Wing et al. 2008 [27] Essadi et al. 2010 [28]
Did the trial address a clearly focused issue? Yes Yes Yes Yes
Was the assignment of patients to treatments
randomised?
Yes N (although described
as randomised)
Yes Can’t tell
Were all of the patients who entered the
trial properly accounted for at its conclusion?
No No Yes Yes
Were patients, health workers and study
personnel ‘blind’ to treatment?
No No (only patients were
blinded)
Yes No (able to differentiate
between juice and water)
Were the groups similar at the start of
the trial?
Yes No (different pregnancy
status)
Yes Yes
Aside from the experimental intervention,
were the groups treated equally?
Yes Yes Yes Can’t tell
How large was the treatment effect? Significant (p = 0.03) Significant (p ≤ 0.001) Not significant (p = 0.71) Significant (p < 0.05)
How precise was the estimate of the
treatment effect?
Precise (95% CI used) Can’t tell (no CI limits) Precise (95% CI used) Can’t tell (no CI limits)
Can the results be applied in your
context? (Or to the local population)
Yes Probable Yes Yes
Were all clinically important outcomes
considered?
Yes Yes Yes Yes
Are the benefits worth the harms and
costs?
Yes Yes N (due to stomach
disturbances)
No (due to stomach
disturbances)
CI Confidence interval. Significance: p ≤ 0.05
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Table 6 Characteristics of included publications
Author, Year, Country Wing et al., 2008, USA [28]
Design Pilot randomised control trial comparing
cranberry juice with placebo.
Participants were divided into three groups and
asked to drink 240 ml of either cranberry or
placebo juice.
A. cranberry juice three times daily
B. cranberry juice once and placebo twice daily
C. placebo three times daily
Note: High withdrawal led to modification of
dose frequency to twice daily in the middle of
the trial. Randomisation was stratified by site.
Aim To determine effectiveness of cranberry juice at
reducing the frequency of ASB.
Participants 188 pregnant women < 16 weeks gestation
Key findings Results report a 57% reduction in bacteriuria
and 41% reduction in all UTIs.
Authors concluded that cranberries provide
protection against ASB as well as symptomatic
infections.
Limitations Small sample size as it was a pilot.
About 39% participants dropped out due to
gastrointestinal issues.
Author, Year, Country Essadi et al., 2010, Libya [29]
Design Randomised control trial comparing cranberry
juice to placebo (water).
Participants were divided into two groups and
asked to drink 250 ml of cranberry juice or water.
A: cranberry juice four times daily
B: water four times daily
Note: This publication is from a conference
poster and full details were not available.
Aim To determine the effectiveness of cranberry juice
at reducing the frequency of UTIs.
Participants 760 pregnant women
Key findings Results report that 70.5% of patients who drank
cranberry juice showed a significant reduction
(p < 0.05) in frequency of UTI compared to
32.16% who drank water.
Of women who developed symptomatic UTI,
4.12% delivered prematurely.
Authors concluded that cranberry juice has a
protective effect in UTI prevention.
Limitations There was no blinding as cranberry juice is
distinguishable from water.
High withdrawal rate of participants (28%)
attributed to gastrointestinal upset.
It is not clear whether authors used intention to
treat analysis which may distort results in favour
of cranberry juice.
Author, Year, Country Elzayat et al., 2017, Egypt [26]
Design An observational study to determine prevalence
of ASB and the risk factors associated with it in
pregnancy. Urine specimens were collected and
analysed to determine ASB. A survey was
conducted using a pre-tested questionnaire to
gather data for the associated risk factors.
Aim To determine the prevalence of ASB and identify
risk factors associated with it in terms of
socioeconomic status or personal hygiene.
Participants 170 pregnant women between the ages of 18–41.
Table 6 Characteristics of included publications (Continued)
Key findings The prevalence of ASB was 10% (CI 95% 5.93%
to 15.53%) in this sample of pregnant women.
There was an association between sexual activity
and incidence of ASB and 14% of women with
ASB reported sexual activity > twice per week
(p = 0.01).
There was also an association between direction
of wiping and 15% of women with ASB reported
wiping their genitals from back to front (p = 0.03).
No other significant association was found.
Authors recommended educating women on the
significance of personal hygiene to prevent UTI
during pregnancy.
Limitations This is an observational study and data was
collected by questionnaire which is subject to
accurate participant recall.
Confidence intervals were not reported for all the
categories.
Author, Year, Country Amiri et al., 2009, Iran [25]
Design An observational case-control study. Cases
(women with UTI) and controls (no UTI) were
matched and compared in terms of difference in
genital hygiene or sexual activity. The women
were administered a questionnaire by a midwife
following which a urine sample was taken for
analysis.
Aim To determine association of genital hygiene and
sexual activity with the frequency of UTIs in
pregnant women.
Participants 250 pregnant women (100 cases and 150 controls)
Key findings The authors investigated multiple factors. Of note
is the significant association seen with:
Sexual activity > thrice a week (OR = 5.62 95%
CI: 3.10–10.10)
Not voiding the bladder after intercourse
(OR = 8.62 95% CI: 6.66–16.66)
Washing genital area from back to front
(OR - 2.96 95% CI: 1.66–5.28)
Limitations This was an observational study and data was
collected using a questionnaire which is subject
to accurate participant recall. Matching of cases
and controls is not reported in detail.
Author, Year, Country Baertschi et al., 2003, Switzerland [33]
Design A before and after study testing a bacterial
extract’s (OM-8930) efficacy and safety in
preventing the incidence of UTIs during
pregnancy.
Aim To determine the effect of immunisation on the
number of UTI recurrences, the number and
duration of antibiotic treatment used and
establish the safety of the vaccine (in women or
new born).
Participants 62 women 16–28 weeks pregnant
Key findings The extract significantly reduced the recurrence
of UTIs from 52.5% to 19.4% (p = 0.002).
Number of people needing antibiotic treatment
reduced from 55.7% to 12.9% (p = 0.0002)
Duration of antibiotic treatment reduced from a
mean of 3.2 to 2 days (p = 0.0016)
The authors concluded that OM-8930 reduced
the number of UTI recurrences but a larger trial
was needed to confirm this result.
Limitations
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inadequate amounts of fluid and delaying voiding of the
bladder also increased the likelihood of UTIs.
The overall evidence from these studies supports the
adoption of protective hygiene behaviours, which may
seem intuitive, as good hygiene is well known to protect
against all types of infections. Women should be pro-
vided with specific recommendations because they may
get upset if they get advised to ‘just keep clean’ as evi-
denced by a qualitative study conducted by Flower et al.
[33].
Cranberry juice
Both RCTs [27, 28] assessing the efficacy of cranberry
juice to prevent UTIs in pregnancy concluded that it has
the potential to be effective. However, both studies had
limitations which shed doubt on the effectiveness of this
intervention. The study by Wing et al. [27] was under-
powered with a small sample size (188 women). Essadi
et al. [28] had a larger cohort (760 women) but com-
pared cranberry juice to water which led to inadequate
blinding giving rise to a risk of performance bias i.e. sys-
temic differences between the groups. In addition, it is
not clear if they used intention-to-treat analysis which
may have distorted the results in favour of cranberry
juice. A point to note with regards to Essadi et al. [28] is
that it was published as a conference poster and full de-
tails were not available but it was included because the
abstract reported data in sufficient detail to determine
the significance of the results.
Table 6 Characteristics of included publications (Continued)
The study compares data from the trial to the 6
month period prior to the study instead of
comparison with a control group. There is a risk
of bias due to this because women’s pregnancy
status would likely be different at the two times.
Also, The study was a pilot and had a small
sample size.
Author, Year, Country Grischke & Ruttgers, 1987, Germany [35]
Design An open comparative randomised trial
comparing effectiveness of a vaccine preparation,
Solco-Urovac®, to standard antibiotic therapy for
prevention of UTIs. The participants were divided
into two groups
Group 1: 200 participants given Solco-Urovac®
(68 were pregnant)
Group 2: 198 participants given nitrofurantoin or
another appropriate antibiotic
Aim To establish the effectiveness of Solco-Urovac®
in reducing the frequency of UTIs.
Participants 400 pregnant and non-pregnant women
Key findings There were 28 infections in the trial group and
84 infections in the control group – this was a
significant difference (p ≤ 0.001).
Average duration of the infection was
significantly longer than in the control group.
No adverse effects were observed in the offspring.
Limitations The study was not conducted exclusively in
pregnant women and their proportion in each
group is not specified.
Randomisation was not done appropriately as the
treating physician may have allocated patients
with acute symptoms to the antibiotic group.
Author, Year, Country Ochoa-Brust et al., 2007, Mexico [36]
Design A randomised trial to assess the prophylactic
role of ascorbic acid in preventing UTIs during
pregnancy. Participants were divided into two
groups.
Group A: treatment with ferrous sulphate 200 mg,
folic acid 5 mg and ascorbic acid 100 mg daily for
3 months
Group B: treatment with ferrous sulphate 200 mg
and folic acid 5 mg daily for 3 months.
Aim To determine the role of ascorbic acid in reducing
the frequency of UTIs.
Participants 110 pregnant women, 55 in each group.
Key findings The infection percentage was 12.7% in Group A
and 29.1% in Group B (p = 0.03, OR 0.35, CI 95%
0.13–0.91).
The relative risk reduction was 56.5% and absolute
risk reduction was 16.3%,
The number needed to treat was 6.
The authors concluded that pregnant women in
areas with high rates of antimicrobial resistance
should take ascorbic acid during gestation to
prevent UTIs.
Limitations Patients were excluded from study if they were
not compliant, had serious side effects or if they
had a UTI recurrence which may have distorted
the results in favour of ascorbic acid.
Author, Year, Country Ordzhonikidze et al., 2009, Russia [38]
Design
Table 6 Characteristics of included publications (Continued)
Two groups of pregnant women were treated
with Canephron® N.
Group 1: 160 women with an exacerbation of
pyelonephritis were given Canephron® N in
combination with standard therapy (antibiotics).
Group 2: 140 women with chronic history of
urinary tract disease who were given Canphron®
N alone for prevention.
The dose of Canephron® N was two tablets three
times a day.
Aim To assess the role of Canephron® N in the
management of urinary tract diseases in pregnant
women.
Participants 300 pregnant women
Key findings Group 2 seemed to show more favourable results
compared to Group 1. The percentage frequency
of exacerbation of pyelonephritis was 10–6.25 in
Group 1 and 3–2.1 in Group 2.
The authors state in the results section that there
was a 1.5-fold decrease in the frequency of
infectious complications in the first group and a
1.3-fold decrease in the second group when
comparing results to previous years.
Limitations The methods, results and analysis have not been
reported clearly.
Canephron® N was not compared to a placebo
or to antibiotics.
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A limitation of cranberry juice seen in both studies was
the high volume of juice that needed to be ingested
(240 ml [27] and 250 ml [28]). Both trials had a high with-
drawal rate mostly due to gastrointestinal disturbances
which can limit its use on grounds of acceptability to
women. These results point to a need to investigate a
standardised content of cranberries in alternative formula-
tions such as tablets and capsules which may help with
improving adherence and tolerability of this intervention.
Both these trials view cranberry juice as potentially
effective at preventing UTIs in pregnancy but a Cochrane
review by Jepson et al. [34] included both these studies in
a meta-analysis and found cranberries to be ineffective in
preventing UTIs in pregnancy. Thus, although there has
been interest in using cranberries for UTI prevention, the
evidence does not support its efficacy. It can still be used
as a self-care option, if preferred by women, because of its
known safety in pregnancy [35, 36].
Immunisation
Both studies investigating the role of immunisation to
safely reduce the recurrence of UTIs in pregnancy found
favourable results, however both had significant limita-
tions. Baertschi et al. [29] used a bacterial extract con-
sisting of different strains of Escherichia coli (E.coli),
which is the most common uropathogen [37], however
this vaccine would not be effective against any other type
of bacteria. Furthermore it was an open pilot study and
did not have a control group to compare the effective-
ness of the vaccine. Therefore, the results need to be
confirmed by a RCT, as noted by the authors themselves.
Grischke and Ruttgers [30] conducted their study in a
sample where 68 pregnant women were given the intra-
muscular vaccine but the number of pregnant women in
the control group was not specified. Blinding was not
clearly described either and so there is an unclear risk of
bias. Therefore, immunisation as an approach to prevent
UTIs in pregnancy needs further exploration to assess
its feasibility in practice.
Ascorbic acid
Ochoa-Brust et al. [31] concluded that daily ascorbic acid
was beneficial especially in areas with a high incidence of
UTIs and antimicrobial resistance. This is a promising
result but requires additional trials to strengthen the
evidence before it can be recommended. It is not clear
whether the authors used intention-to-treat analysis be-
cause they did not specify the withdrawal rate and there
was a selection bias as they excluded women who were
non-adherent or had ‘serious side effects’ from the medi-
cation. Excluding these results from analysis may distort
the results in favour of ascorbic acid. It is worth noting,
however, that no harmful effects were observed in the off-
spring of women who ingested ascorbic acid daily.
Canephron® N
Canephron® N is a phytotherapeutic medicine with anti-
bacterial properties and contains three herbs namely rose-
mary, lovage and centaury [38]. It is manufactured by a
German company, Bionorica®, which focuses on research-
ing and developing plant-based medicines. Ordzhonikidze
et al. [32] conducted a study with pregnant women using
this product, to optimise management of urinary tract dis-
eases including ASB and pyelonephritis, which concluded
that it could be recommended for prevention of urinary
tract complications in pregnancy. The reporting of results
was not comprehensive so it was not possible to deter-
mine how the study was conducted in sufficient detail (see
Table 3). A review by Naber et al. [38] assessing the effi-
cacy of Canephron® N suggests that there might be some
benefit from its use in pregnant women because it in-
cluded evidence from additional studies which have not
been discussed here as they were conducted in pregnant
women with co-morbidities and so did not meet the inclu-
sion criteria of this review. It is worth noting that the
safety of Canephron® N in pregnancy has been established
[39, 40] but in order to make an evidence based recom-
mendation, its efficacy needs to be confirmed by a rando-
mised controlled trial.
Strengths and limitations
A total of ten databases were searched and search terms
were mutually agreed by the authors and an independent
colleague to ensure a comprehensive process. The stud-
ies included in the review were assessed independently
by the authors using CASP checklists. Any disagreement
was resolved by meeting and discussing the relevant
studies. A limitation of this review is that only English
language publications were included therefore there
might be options which have not been identified. The re-
sults of this review have been discussed using a narrative
synthesis approach due to the heterogeneous design of
the included studies and the differing nature of the inter-
ventions identified.
Conclusion
All the approaches identified in this review are reported
to be safe and effective. However apart from hygiene
behaviours, the evidence behind these approaches is not
robust enough to be recommended in practice. Future
work needs to focus on strengthening the evidence base
through improved design and reporting of clinical trials,
in particular for the use of immunisation, ascorbic acid
and Canephron® N. It is important that evidence based
non-antibiotic measures to prevent UTIs in pregnancy
are discovered to combat the danger that antimicrobial
resistance poses to the health of this vulnerable patient
group as well as the wider population.
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